Novartis’ Kisqali in a new analysis showed a 28.5% reduction in the risk of breast cancer recurrence in patients with early breast cancer. The benefit continued after the three-year treatment, consistent across all patient subgroups. Safety profile remains good, with low-grade adverse events. Results will be presented at ESMO, with FDA action expected in Q3. Kisqali added to endocrine therapy proved beneficial in reducing recurrence risk. The trial included a broad population, emphasizing the importance of reducing recurrence risk in early breast cancer patients.